Form 4: SAB Biotherapeutics Director Erick Lucera Acquires 20,000 Stock Options

Director Erick Lucera reports acquisition of 20,000 stock options in SAB Biotherapeutics, Inc. as part of the annual board grant.

Summary

• Erick Lucera, a director of SAB Biotherapeutics, Inc., filed a Form 4 disclosing a transaction involving the acquisition of stock options.
• On July 15, 2024, Lucera acquired 20,000 stock options with an exercise price of $2.90.
• These options are part of the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.
• The options vest in two equal annual installments on July 15, 2025, and July 15, 2026.
• Following the transaction, Lucera directly owns 20,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which is neither particularly positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates